Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pamidronate disodium, risedronic acid, risedronate sodium +8 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 1,320 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13976
Sealed predictions
- FDPS in dopamine neurons, braak-0.69 (p 0.038) → -0.35 (p 0.360)receipt 13983
Swarm cases
receipt 13983: FDPS in dopamine neurons, braak
- power
- full sample -0.51 (p 0.032, n 18), 95% CI -0.79 to -0.05. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.033, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.033, n 18). not the mix.
- skeptic
- leave-one-out range -0.61 to -0.45, sign flips 0; without severely affected donors -0.51 (p 0.032, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FDPS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts